About: The MOLES System for Planning Management of Melanocytic Choroidal Tumors: Is It Safe?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The MOLES System for Planning Management of Melanocytic Choroidal Tumors: Is It Safe? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The MOLES System for Planning Management of Melanocytic Choroidal Tumors: Is It Safe?
Creator	Al Harby, Lamis Arora, Amit Cohen, Victoria Damato, Bertil Roelofs, Kelsey Sagoo, Mandeep O'day, Roderick
Source	Medline; PMC
abstract	Purpose: To evaluate the MOLES system for identifying malignancy in melanocytic choroidal tumors in patients treated for choroidal melanoma. Methods: Records of 615 patients treated for choroidal melanoma between January 2017 and December 2019 were reviewed. Patients were excluded if iris and/or ciliary body involvement (106 patients), inadequate fundus photography (26 patients), no images available for review (21 patients) and/or treatment was not primary (11 patients). Demographic data and AJCC TNM Stage were collected. Color fundus and autofluorescence photographs (FAF), optical coherence tomography (OCT) and B-scan ultrasounds were prospectively reviewed. MOLES scores were assigned according to five criteria: mushroom shape, orange pigment, large size, enlarging tumor and subretinal fluid. Results: A total of 451 patients (mean age, 63.9 ± 13.9 years) were included. At treatment, mean largest basal tumor diameter (LBD) and thickness were 10.3 ± 2.8 mm (range, 3.0–23.0) and 4.3 mm (range, 1.0–17.0). All but one (0.2%) had MOLES scores of ≥3. Eighty-two patients were treated after surveillance lasting a mean of 1.5 years. Initially, most (63/82; 76.8%) had a MOLES score ≥ 3. Importantly, none of the 451 tumors had a score of <2, and as such, the MOLES protocol would have indicated referral to an ocular oncologist for 100% of patients. Conclusion: The MOLES scoring system is a sensitive (99.8%) tool for indicating malignancy in melanocytic choroidal tumors (MOLES ≥ 3). If the examining practitioner can recognize the five features suggestive of malignancy, MOLES is a safe tool to optimize referral of melanocytic choroidal tumors for specialist care.
has issue date	2020-05-21(xsd:dateTime)
bibo:doi	10.3390/cancers12051311
bibo:pmid	32455720
has license	cc-by
sha1sum (hex)	23dd3610a2c1eb987089aa89236b19adcc2bc7bd
schema:url	https://doi.org/10.3390/cancers12051311
resource representing a document's title	The MOLES System for Planning Management of Melanocytic Choroidal Tumors: Is It Safe?
has PubMed Central identifier	PMC7281649
has PubMed identifier	32455720
schema:publication	Cancers (Basel)
resource representing a document's body	covid:23dd3610a2c1eb987089aa89236b19adcc2bc7bd#body_text
is schema:about of	named entity 'COLOR' named entity 'SCORE' named entity 'OPTICAL COHERENCE TOMOGRAPHY' named entity 'ONCOLOGIST' named entity 'SHAPE' named entity '4.3' named entity '13.9' named entity 'TNM' named entity 'tumor' named entity 'tumors' named entity 'oncologist' named entity 'tumors' named entity 'mushroom' named entity 'AJCC' named entity 'Choroidal' named entity 'autofluorescence' named entity 'subretinal' named entity 'oncologists' named entity 'nevi' named entity 'tumors' named entity 'ultrasonography' named entity 'blood flow' named entity 'melanomas' named entity 'tumors' named entity 'Lipofuscin' named entity 'nevi' named entity 'nevi' named entity 'nevi' named entity 'Lipofuscin' named entity 'interquartile range' named entity 'tumors' named entity 'tumors' named entity 'ultrasonography' named entity 'malignancy' named entity 'pathognomonic' named entity 'Blue Mountain' named entity 'melanomas' named entity 'metastasis' named entity 'Melanoma' named entity 'tumor' named entity 'risk factor' named entity 'risk factors' named entity 'optical coherence tomography' named entity 'risk factors' named entity 'melanomas' named entity 'fovea' named entity 'uveal melanoma' named entity 'tumor' named entity 'mnemonic' named entity 'tumor' named entity 'metastatic spread' named entity 'nevi' named entity 'high-risk' named entity 'clinical examination' named entity 'risk factor' named entity 'Orange pigment' named entity 'nevus' named entity 'statistical significance' named entity 'ultrasonography' named entity 'tumor' named entity 'malignancy' named entity 'slow-growing' named entity 'ora serrata' named entity 'choroidal melanoma' named entity 'Lipofuscin' named entity 'melanocytic tumors' named entity 'Oxford Eye Hospital' named entity 'clinical signs' named entity '5.1' named entity 'nevi' named entity 'melanocytic tumors' named entity 'melanoma' named entity 'nevi' named entity 'nevi' named entity 'melanomas'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software